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Epidemiological studies have identified many risk factors for osteoporosis, however
it is unclear whether these observational associations reflect true causal effects, or
the effects of latent confounding or reverse causality. Mendelian randomization (MR)
enables causal relationships to be evaluated, by examining the relationship between
genetic susceptibility to the risk factor in question, and the disease outcome of interest.
This has been facilitated by the development of two-sample MR analysis, where the
exposure and outcome are measured in different studies, and by exploiting summary
result statistics from large well-powered genome-wide association studies that are
available for thousands of traits. Though MR has several inherent limitations, the field
is rapidly evolving and at least 14 methodological extensions have been developed to
overcome these. The present paper aims to discuss some of the limitations in the MR
analytical framework, and how this method has been applied to the osteoporosis field,
helping to reinforce conclusions about causality, and discovering potential new regulatory
pathways, exemplified by our recent MR study of sclerostin.
Keywords: bone mineral density (BMD), fractures - bone, pleiotropy, sclerostin, GWAS - genome-wide association
study
INTRODUCTION
Osteoporosis is a common disorder leading to skeletal fragility and increased fracture risk. This
condition is strongly influenced by age and sex, as well as genetic factors. Establishing which risk
factors play a causal role in osteoporosis is helpful in unraveling pathogenic mechanisms, and
in identifying potential new preventative and treatment strategies. Epidemiology studies in the
osteoporosis field have examined relationships between putative risk factors and fracture risk, the
main clinical consequence of osteoporosis. Investigations have also studied risk factors for bone
mineral density (BMD) as measured by DXA, which is a strong predictor of fracture risk (1).
Traditional observational studies have reported that a range of potentially modifiable risk factors,
including sex-steroid deficiency, low body mass index (BMI), physical inactivity, smoking, heavy
alcohol consumption, and low calcium and vitamin D, are related to BMD and fractures. However,
studies of this type suffer from confounding and reverse causality (2, 3). Randomized controlled
trials (RCTs) are the gold standard for inferring causality, because they are unaffected by these
issues if performed correctly. However, RCTs are expensive, resource-intensive, time consuming,
and may have important ethical limitations.
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MR is a statistical method for inferring causality which
is analogous to an RCT, except that genotypes are used
to randomize participants into different levels of the
exposure/treatment. MR can be implemented as a form of
instrumental variables analysis, where genetic variants, normally
single nucleotide polymorphisms (SNPs), are used as proxies
(“instruments”) for the exposure of interest (see Figure 1) (4, 5).
According to Mendel’s Laws of Inheritance, alleles segregate
randomly when passed from parents to offspring. According
to his (second) Law of Independent Assortment, which forms
the foundation of MR, the inheritance of one pair of factors
(genes) is independent of the inheritance of the other pair.
Thus, offspring genotypes are unlikely to be associated with
confounders in the population. In addition, since germ-line
genotypes are determined at conception, they precede outcomes
being investigated, and so observed associations cannot be
explained by reverse causation. However, unlike RCTs which
generally involve relatively short term interventions, genetic
influences exert their effects from conception onwards, and so
causal effects estimated fromMR represent life-long exposures.
MR was initially developed in the form of one-sample MR,
which relies on access to individual level data (Figure 1A). One
limitation of this method is that most individual cohorts do not
have many traits measured simultaneously. Two sample MR was
subsequently developed to overcome this issue by using summary
level data derived from independent cohorts that collectively have
many exposures and outcomes measured (Figure 1B). GWAS
data is now available on thousands of plausible osteoporosis risk
factors which can be leveraged by two sample MR. The extensive
opportunities to explore causal influences on bone phenotypes
using the MR approach is summarized in two recent reviews
(2, 5).
Though previous MR studies have contributed to our
understanding of causal factors involved in the etiology of
osteoporosis, as discussed below, MR has a number of inherent
assumptions and limitations, for which a range of sensitivity
analyses have been developed (6–8). MR analyses may also be
subject to several sources of bias (9). For example, if individuals
with a certain disease outcome are drawn from a population
with distinct ancestry to disease-free controls, this may lead
to differences in frequency of genetic variants between those
with and without disease, and hence spurious associations
with genotypes related to putative risk factors. Furthermore,
dynastic effects need to be considered for many traits, including
BMD, whereby effects of genetic variation in the offspring are
partly mediated by shared parental genetic influences acting
via early life environment (10). The present paper aims to
discuss how MR has been applied to the osteoporosis field,
including the approaches taken to address limitations in the MR
analytical framework.
OSTEOPOROSIS OUTCOMES
Consistent with epidemiology studies of osteoporosis in general,
the majority of MR studies in osteoporosis have utilized DXA-
measured BMD as the outcome, which is widely used clinically
as the gold standard for diagnosing osteoporosis. As well as
being predictive of the clinical consequence of osteoporosis,
namely fractures (1), BMD has a major heritable component,
making it a highly suitable outcome for MR analyses (11, 12).
Initial studies utilized summary statistics from GWASs, such as
those based on the GEnetic Factors for OSteoporosis Consortium
(GEFOS, http://www.gefos.org/), which made GWAS findings
for DXA-measured BMD publicly available for a range of sites
including the lumbar spine (LS) and femoral neck (FN) (13).
Whereas, GEFOS has the advantage of providing BMD GWAS
data for multiple skeletal sites, a potential disadvantage is that
the latter GWAS adjusted for weight. The justification for this
is that areal BMD measured by DXA is influenced by body
size, which is partly accounted for by adjusting for weight.
However, this can have unintended consequences, such as the
introduction of spurious genetic associations as a consequence of
collider bias (14). In addition, by using BMD summary statistics
corrected for weight, subsequent MR analysis may be biased
as effects on BMD mediated by weight may not be accurately
estimated. Moreover, as described below, use of GWAS outputs
that were adjusted for weight and/or height may complicate
interpretation when applying these data inMR studies examining
relationships between BMI and BMD. The latter relationship is
thought to be relatively complex, involving both a mass effect
leading to greater loading acting via the mechanosensor, and
shared endocrine pathways.
Recently published GWASs for estimated BMD (eBMD)
derived from heel ultrasound in UK Biobank (11, 12) have
the advantage that both unadjusted and adjusted summary
statistics are available on request, enabling sensitivity analyses
to be performed. Moreover, the large sample size provides
a significant advance in terms of power, which is one of
the major limitations of MR studies. Ultrasound derived
BMD does not involve radiation, is quick and cheap, and is
therefore well-suited to population studies involving hundreds
of thousands of people. The limitation is that estimated
BMD is not well-understood and we are not entirely sure
how well it proxies BMD. That said, eBMD and DXA-BMD
measures are reasonably highly correlated genetically (r =
∼0.5), as are eBMD and fractures (r = ∼0.5) (11), and
ultrasound-derived measures have previously been reported to
predict subsequent fractures with similar accuracy to DXA
BMD (15–18).
BMD is an intermediary phenotype; low BMD is only of
pathological significance as a result of its causal relationship with
fracture. However, since many risk factors for osteoporosis act
via BMD, their relationship with BMD is somewhat stronger
than that with fracture, with the result that MR studies using
fracture as the outcome tend to be underpowered. That said,
in a large MR study of fractures based on discovery set of
37,857 fracture cases and 227,116 controls, with replication
in 147,200 fracture cases and 150,085 controls, Trajanoska
et al. found that higher BMD had an expected causal
effect in reducing fractures (19). Moreover, Morris et al.
identified 13 bone fracture loci in approximately 1.2 million
individuals, all of which were associated with eBMD (12). It
may also be possible to extend MR studies in osteoporosis
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FIGURE 1 | One-sample and two-sample Mendelian randomization study designs. (A) One-sample Mendelian randomization is based on a population where both
exposure and outcome have been measured. (B) In two-sample Mendelian randomization, exposures and outcomes are measured in non-overlapping populations.
SNP-exposure is derived in Sample 1, and SNP-outcome in Sample 2.
to examine causal effects on other phenotypes relevant to
osteoporosis. BMD is not the sole causal determinant of
fracture, and GWAS signals have recently been identified for
several geometric parameters derived from hip DXA, which
are also thought to be related to fracture risk (20). GWAS
efforts are also underway for osteocalcin and CTX, offering
opportunities for MR studies to examine causal pathways
for other outcomes contributing to fracture risk, such as
bone turnover.
OSTEOPOROSIS RISK FACTORS
A range of risk factors for osteoporosis identified in
epidemiological studies have been examined in MR studies
intended to explore their causal effects, using BMD as the
outcome, the majority of which have yielded no or weak
evidence of causality (see Table 1). For example, studies using
BMD as an outcome did not find support for a causal effect
of vitamin D (21–23) or genetically determined calcium
intake as reflected by lactase persistence genotype (24). Guo
et al. found no evidence to suggest a causal effect of alcohol
consumption on BMD whereas smoking status was found
to be causally related to lower BMD (25); however, it should
be noted that smoking (exposure) and eBMD (outcome)
instruments were derived from the same sample population
which could result in biased estimates (8). In a subsequent study,
genetic predisposition to smoking initiation was associated
with fracture risk, but not eBMD; genetic liability to alcohol
dependence was also associated with fracture and lower eBMD,
whereas no association was seen for genetically predicted
alcohol intake (26). However, this study also included UK
Biobank participants in exposure and outcome instruments
which could lead to bias. Other studies exploring the effect of
serum urate (27, 28), inflammatory markers (29) and thyroid
stimulating hormone (30) found no evidence for association
with FN or LS BMD. Rather than a risk factor, MR analysis
suggests that lowering LDL-C levels and statin therapy improve
BMD (31).
In terms of constitutive factors, a causal association was
observed between later age at menarche and reduced FN and
LS BMD in adults (32), and reduced LS BMD in adolescents
(33). A study in children found a causal association between
BMI/adiposity and BMD (34). A previous study in adults using
summary data from GWASs in Europeans found no evidence
of a causal effect of BMI (based on 77 SNPs) on FN or LS
BMD, however since FN and LS BMD were corrected for
weight prior to the GWAS, the variation in BMD attributable
to BMI may not be adequately captured by MR analysis (35). In
contrast, a one-sample MR in Koreans using 13 BMI-associated
SNPs identified in a GWAS of east Asians was suggestive of
a causal effect of BMI on BMD on weight bearing sites in
men and pre-menopausal women (36). Observation studies have
implicated several diseases in the development of osteoporosis,
however MR has subsequently found no causal effect of type 2
diabetes (T2D) and coronary heart disease (CHD) on eBMD (37).
Another study reported a weak association between increased
T2D risk and increased FN BMD, whereas no association was
seen with LS BMD (35). In terms of other constitutional factors,
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TABLE 1 | Examples of studies investigating causal associations between risk factors and BMD.
Exposure Sample source for
exposure
Genetic
variants (n)
Outcome Sample size and data
source for outcome
Method Evidence of
causal effect
(Yes/No)
References
Vitamin D Chinese populations 10 LS BMD Postmenopausal Chinese
women, N = 1,824
One-sample No (21)
10 FN BMD
10 Total hip BMD
10 LS BMD
10 FN BMD
10 Total hip BMD
Vitamin D Europeans,
N = 79,366
6 TB BMD Individuals from Europe
(86%), America (2%) and
Australia (14%), N = 66,628
Two-sample (IVW) No (22)
Vitamin D Europeans,
N = 42,274
(SUNLIGHT
consortium)
5 DXA FN BMD Europeans, N = 32,965
(GEFOS Consortium)
Two-sample (weighted
median)
No (23)
5 DXA LS BMD
5 eBMD Europeans, N = 142,487
(UK Biobank)
Milk intake Lactase persistence
SNP in the MCM6
gene, based on
previous studies
1 Forearm BMD Europeans, N = 53,236
(GEFOS Consortium)
Two-sample (Wald
estimate)
No (24)
1 FN BMD
1 LS BMD
Alcohol
consumption
Europeans 6 FN BMD Europeans, N = 32,735
(GEFOS Consortium)
Two-sample (IVW) No (25)
6 LS BMD Europeans, N = 28,498
(GEFOS Consortium)
6 Forearm BMD Europeans, N = 8,143
(GEFOS Consortium)
5 Heel BMD Europeans, N = 445,921
(UK Biobank)
Smoking status Europeans (including
UKBB results)
142 FN BMD Europeans, N = 32,735
(GEFOS Consortium)
Two-sample (IVW) No
142 LS BMD Europeans, N = 28,498
(GEFOS Consortium)
139 Forearm BMD Europeans, N = 8,143
(GEFOS Consortium)
142 Heel BMD Europeans, N = 445,921
(UK Biobank)
Two-sample (IVW) Some
evidence but
could be
biased
Smoking initiation Europeans (including
UKBB results)
1 FN BMD Europeans, N = 32,735
(GEFOS Consortium)
Two-sample (IVW) No
1 LS BMD Europeans, N = 28,498
(GEFOS Consortium)
1 Forearm BMD Europeans, N = 8,143
(GEFOS Consortium)
1 Heel BMD Europeans, N = 445,921
(UK Biobank)
Two-sample (IVW) Some
evidence but
could be
biased
No. of cigarettes
smoked per day
(CPD)
Europeans (Tobacco
and Genetics
Consortium)
3 FN BMD Europeans, N = 32,735
(GEFOS Consortium)
Two-sample (IVW) Very weak
evidence
3 LS BMD Europeans, N = 28,498
(GEFOS Consortium)
Two-sample (IVW) No
3 Forearm BMD Europeans, N = 8,143
(GEFOS Consortium)
No
3 Heel BMD Europeans, N = 445,921
(UK Biobank)
No
(Continued)
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TABLE 1 | Continued
Exposure Sample source for
exposure
Genetic
variants (n)
Outcome Sample size and data
source for outcome
Method Evidence of
causal effect
(Yes/No)
References
Smoking initiation Europeans
N = 1,232,091
(including UK Biobank)
376 eBMD Europeans, N = 426,824
(UK Biobank)
Two-sample (IVW) No (26)
DXA derived BMD Europeans N = 32,965
(GEFOS Consortium)
Two-sample (IVW) No
Genetically
predicted alcohol
intake
Europeans
N = 941,280
(including UK Biobank)
96 eBMD Europeans, N = 426,824
(UK Biobank)
Two-sample (IVW) No
DXA derived BMD Europeans N = 32,965
(GEFOS Consortium)
Two-sample (IVW) No
Genetic liability to
alcohol dependence
Europeans
N = 46,568 (11,569
cases and 34,999
controls)
1 eBMD Europeans, N = 426,824
(UK Biobank)
Two-sample (IVW) Yes
1 DXA derived BMD Europeans N = 32,965
(GEFOS Consortium)
Two-sample (IVW) No
Serum urate Europeans 5 LS BMD 1,322 postmenopausal
women and elderly men
from Shanghai
One-sample No (27)
5 FN BMD
5 Total hip BMD
Serum urate Europeans 3 Total hip BMD Generation 3 cohort in the
Framingham Heart Study
(N = 2,501)
One-sample No (28)
3 FN BMD
3 LS BMD
Inflammatory
markers - hsCRP
Europeans 16 Forearm BMD Europeans, N = 32,965
(GEFOS Consortium)
Two-sample (IVW) No (29)
16 FN BMD
16 LS BMD
Thyroid Stimulating
Hormone
Europeans,
N = 26,420
20 FN BMD Europeans, N = 28,498
(GEFOS Consortium)
Two-sample (IVW) No (30)
20 LS BMD
Low LDL-C levels Global Lipids Genetics
Consortium
N = 188,577
76 TB BMD Populations from America,
Europe and Australia
N = 66,628
Two-sample (IVW) Some
evidence
(31)
Multivariable IVW No
76 eBMD Europeans, N = 142,487
(UK Biobank)
Two-sample (IVW) Yes
Multivariable IVW Yes
Gene encoding
molecular target of
LDL-C-lowering
therapy (HMGCR)
Global Lipids Genetics
Consortium
N = 188,577
3 TB BMD Populations from America,
Europe and Australia
N = 66,628
Two-sample (IVW) Yes
3 eBMD Europeans, N = 142,487
(UK Biobank)
Two-sample (IVW) Yes
AAM European women
ReproGen Consortium
N = 182,416
116 LS BMD GEFOS Consortium (N =
53,236) (both males and
females)
Two-sample (IVW) Yes (32)
116 FN BMD
AAM on aBMD in
adolescent girls
ReproGen Consortium 331 LS BMD aBMD in childhood/
adolescence (BMDCS)
Two-sample (FE
meta-analysis)
Yes (33)
331 FN BMD No
331 Distal radius No
AAM on aBMD in
adult women
ReproGen Consortium 309 LS BMD GEFOS Consortium Two-sample (FE
meta-analysis)
Yes
309 FN BMD Yes
309 Distal radius No
AVB on aBMD in
adolescent boys
ReproGen Consortium 43 LS BMD aBMD in childhood/
adolescence (BMDCS)
Two-sample (FE
meta-analysis)
No
43 FN BMD No
43 Distal radius No
AVB on aBMD in
adult men
ReproGen Consortium 42 LS BMD GEFOS Consortium Two-sample (FE
meta-analysis)
Yes
42 FN BMD Yes
42 Distal radius No
(Continued)
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TABLE 1 | Continued
Exposure Sample source for
exposure
Genetic
variants (n)
Outcome Sample size and data
source for outcome
Method Evidence of
causal effect
(Yes/No)
References
BMI Europeans 32 SK-BMD Europeans, N = 5,221
(ALSPAC cohort)
*N = 4,223 for SK-BMD
One-sample No (34)
32 UL-BMD Yes
32 LL-BMD Yes
32 SP-BMD Yes
32 PE-BMD Yes
Fat mass Europeans 32 SK-BMD Europeans, N = 5,221
(ALSPAC cohort)
*N = 4,223 for SK-BMD
One-sample No
32 UL-BMD Yes
32 LL-BMD Yes
32 SP-BMD Yes
32 PE-BMD Yes
Fat mass Europeans 32 SK-BMD Europeans, N = 5,221
(ALSPAC cohort)
*N = 4,223 for SK-BMD
One-sample
multivariable MR
No
32 UL-BMD No
32 LL-BMD Yes
32 SP-BMD Yes
32 PE-BMD Yes
Lean mass Europeans 32 SK-BMD Europeans, N = 5,221
(ALSPAC cohort)
*N = 4,223 for SK-BMD
One-sample
multivariable MR
No
32 UL-BMD Yes
32 LL-BMD Yes
32 SP-BMD No
32 PE-BMD Yes
BMI GIANT consortium 77 FN BMD Europeans, GEFOS 2012 Two-sample (IVW) No (35)
77 LS BMD No
BMI East Asian populations 13 Weight-bearing
bones
Men, N = 1,110 One-sample Yes (36)
13 Non–weight-bearing
bones
Yes
13 Skull No
13 Weight-bearing
bones
Premenopausal women,
N = 1,015
One-sample Yes
13 Non–weight-bearing
bones
No
13 Skull No
13 Weight-bearing
bones
Postmenopausal women,
N = 32
One-sample No
13 Non–weight-bearing
bones
No
13 Skull No
T2D DIAGRAM: 26,676
T2D cases and
132,532 controls
94 eBMD ∼150,000 UK Biobank
participants
Two-sample (IVW) No (37)
CHD CARDIoGRAMplusC4D 52 eBMD ∼150,000 UK Biobank
participants
Two-sample (IVW) No
T2D DIAGRAM consortium 32 FN BMD GEFOS, N = 83,894 Two-sample (IVW) Weak
evidence
(35)
32 LS BMD No
Metabolites Europeans 481 blood
metabolites
Hip BMD 2,286 unrelated white
subjects for the discovery
samples
Pearson correlation Associations
between BMD
and 54 blood
metabolites
(38)
Total serum calcium Europeans (discovery
cohort N = 39,400,
replication cohort
N = 21,676)
7 eBMD Europeans, N = 426,824
(UK Biobank)
Two-sample (IVW) No (39)
LS, lumbar spine; FN, femoral neck; TB, total body; eBMD, estimated bone mineral density; AAM, age at menarche; AVB, age at voice break; UL, upper limbs; LL, lower limbs; SP,
spine; PE, pelvis; IVW, inverse-variance weighted; T2D, type 2 diabetes; CHD, coronary heart disease; BMI, body mass index; FE, fixed-effects.
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genetic predisposition to increased calcium levels was recently
found to be unrelated either to eBMD or fracture risk in UK
Biobank (39).
Several MR studies have examined osteoporosis risk factors
with fracture as the outcome (Table 2). In the study based
on UK Biobank from Trajanoska et al. (19), while confirming
the expected protective effect of higher BMD on fractures,
there was little evidence to suggest a causal effect of dietary
factors (vitamin D levels and calcium intake), early menopause,
late puberty and range of diseases (including type 1 and 2
diabetes, CHD and inflammatory bowel disease) on risk of
fracture. These findings are consistent with results from the
above MR studies based on BMD. However, the study did
provide some evidence for causal effect of decreased grip strength
on fracture risk. A study in 97,811 Danish individuals failed
to provide evidence for a relationship between calcium intake
and hip fracture (40). Interestingly, an MR study investigating
the causal effect of height with 50 diseases reported that one
SD increase in genetically determined height was associated
with increased risk of hip fracture (41). In terms of the effect
of serum hormones, a previous MR study in men reported
lower levels of estradiol to be causally related to increased
risk of fracture (including all self-reported fractures, major
non-vertebral osteoporotic fractures and wrist fractures), whilst
there was no evidence for causal association between serum
testosterone and fracture risk (42). Furthermore, using a genetic
risk score for CRP levels in a Rotterdam study, there was
no evidence to support a causal effect of CRP on fracture
risk (43).
Some MR studies have set out to test hypothesized causal
effects of BMD on other outcomes. For example, in a study which
used summary statistics from the first release of the UK Biobank
data (N = 11,650), the authors reported some evidence for a
causal effect of eBMD on T2D, CHD, HDL-c, and HOMA-IR,
testing reciprocal associations for two traits (T2D and CHD), for
which there was no evidence of a causal effect on BMD (37). The
most recent study in 426,824 UK Biobank participants identified
518 loci associated with eBMD, explaining 20% of its variance
(12), meaning that many powerful and robust instruments for
MR analyses examining causal effects of eBMD will be available.
ADDRESSING PLEIOTROPY
Key points:-
1. Vertical pleiotropy, when the genetic variant has an effect
on two or more traits that both influence the outcome via
the same biological pathway, is usually not problematic for
MR analyses
2. In contrast, horizontal pleiotropy, when a genetic variant
is associated with two traits which influence the outcome
via independent biological pathways, violates one of the key
MR assumptions
3. Several methods have been developed that relax the strict
requirement that genetic instruments exhibit no horizontal
pleiotropy yet still produce consistent causal effect estimates
4. Where genetic instruments are known to be pleiotropically
associated with multiple correlated phenotypes, it may be
possible to examine independent effects through exclusion of
certain SNPs, or use of multivariable MR.
One of the main assumptions of MR is that genetic instruments
are only associated with the interest via the exposure being
tested. This is known as the “no pleiotropy” assumption or
the “exclusion restriction criterion.” When performing an MR
study, it is usually unclear whether such an assumption holds.
Therefore, various sensitivity analyses are applied to detect the
existence of pleiotropy, and to estimate the un-biased causal effect
of the exposure on the outcome. Vertical pleiotropy (i.e., a genetic
variant has an effect on two or more traits that both influence
the outcome via the same biological pathway) is not generally
an issue for MR analysis (Figure 2A) (8). However, this can be
this can be problematic in situations where the exposure variable
is mis-specified i.e., the genetic instrument is biologically related
to an intermediate or outcome, but has been identified as being
related to the exposure by virtue of the latter’s correlation with the
biologically related trait (4), termed correlated pleiotropy (44).
For example, although a locus in FTO was initially identified
in relation to type II diabetes, this was subsequently found
to primarily influence BMI with secondary effects on type II
diabetes (45), leading to difficulties in interpreting MR studies
where FTO variation is used as instrumental variable for type
2 diabetes.
In contrast, horizontal pleiotropy (i.e., a genetic variant
is associated with two traits which influence the outcome
via independent biological pathways) violates the exclusion
restriction criterion (Figure 2B). GWAS identify genetic
instruments purely on statistical grounds. Even if instrumental
variables used in MR studies intersect genes with plausible
pathways to the exposure it’s not possible to be sure whether they
mediate the causal effect being evaluated. Therefore, potential
horizontal pleiotropy as a result of unknown pathways needs to
be excluded if MR studies are to reach robust conclusions about
causality. One simple method to limit the impact of horizontal
pleiotropy is leave-one-out as a sensitivity analysis to ensure
that the causal effect is not mediated by an outlier effect of one
specific locus (46).
Over the last few years, several methods have been developed
that relax the strict requirement that genetic instruments exhibit
no horizontal pleiotropy yet still produce consistent causal effect
estimates (7). One such approach is MR-Egger regression (47),
where given a set of genetic variants that proxy an exposure
variable of interest, a regression is performed between estimates
of the SNP-outcome association and SNP-exposure association
(this can be performed in both one and two-sample MR
analyses). Unfortunately, Egger regression is limited by very poor
power. Weighted median and weighted mode approaches have
since been developed to derive causal estimates based on the
relationship between the strength of the association between the
SNP and the outcome, and the strength of the association of the
SNP with the exposure, which are more robust to violation of
horizontal pleiotropy by a substantial proportion of instruments
(48, 49). Several additional methods now exist which assume
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TABLE 2 | Examples of MR studies using fracture as an outcome.
Exposure Sample source for
exposure data
Genetic
variants (n)
Outcome Sample size and data
sources for the outcome
data
MR method Evidence of
causal effect
(Yes/No)
References
Decreased FN
BMD
Europeans 43 Fractures at any skeletal
site confirmed by medical,
radiological, or
questionnaire reports
147,200 cases and
150,085 controls (primarily
of European ancestry)
Two-sample (IVW) Yes (19)
Decreased LS
BMD
40 Yes
Earlier
menopause
54 No
Rheumatoid
arthritis
30 No
Inflammatory
bowel disease
19 No
Type 1 diabetes 151 No
Decreased THS 20 No
Homocysteine 13 No
Decreased Grip
strength
15 Yes
Late puberty 106 Some evidence
Fasting glucose 35 No
Coronary heart
disease
38 No
Type 2 diabetes 38 No
Vitamin D 4 No
Dairy calcium
intake
1 No
Lactase
persistence
LCT-13910 C/T
genetic variant
Northern Europeans 1 Hip fracture 97,811 Danish individuals Fixed effects
meta-analysis
No (39)
Height Europeans,
N = 253,288 (GIANT)
697 Hip fracture 2,451 fracture cases of
417,434 individuals from
UK Biobank
Two-sample (IVW) Yes (40)
Serum estradiol Europeans 2 All self-reported fractures Europeans, N = 17,650
(UK Biobank)
Two-sample (IVW) Yes (41)
2 Major nonvertebral
osteoporotic fractures
(N = 4,379; wrist, arm, and
hip)
2 Wrist fractures (N = 2,637)
Testosterone Europeans 3 All self-reported fractures (N = 17,650) No
3 Major nonvertebral
osteoporotic fractures
(N = 4,379; wrist, arm, and
hip)
3 Wrist fractures (N = 2,637)
Serum CRP
levels
Europeans 29 Any fracture 6,386 participants (59%
women), of whom 1,561
sustained a fracture
One-sample No (42)
Smoking
initiation
Europeans
N = 1,232,091
(including UK Biobank)
377 Any fracture (excluding
skull, face, hands and
feet, pathological fractures
due to malignancy,
atypical femoral fractures,
periprosthetic, and healed
fracture) and any
self-reported fractures
Europeans N = 426,795
(53,184 cases and
373,611 non-cases) (UK
Biobank)
Two-sample (IVW) Yes (26)
Genetically
predicted
alcohol intake
Europeans N =
941,280 (including UK
Biobank)
99 Any fracture (excluding
skull, face, hands and
feet, pathological fractures
due to malignancy,
atypical femoral fractures,
periprosthetic, and healed
fracture) and any
self-reported fractures
Europeans N = 426,795
(53,184 cases and
373,611 non-cases) (UK
Biobank)
Two-sample (IVW) No
(Continued)
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TABLE 2 | Continued
Exposure Sample source for
exposure data
Genetic
variants (n)
Outcome Sample size and data
sources for the outcome
data
MR method Evidence of
causal effect
(Yes/No)
References
Genetic liability
to alcohol
dependence
Europeans N =
46,568 (11,569 cases
and 34,999 controls)
2 Any fracture (excluding
skull, face, hands and
feet, pathological fractures
due to malignancy,
atypical femoral fractures,
periprosthetic, and healed
fracture) and any
self-reported fractures
Europeans N = 426,795
(53,184 cases and
373,611 non-cases) (UK
Biobank)
Two-sample (IVW) Some evidence
LDL-C levels N = 188,577 (GLSC) 76 Fractures at any skeletal
site confirmed by medical,
radiological, or
questionnaire reports
147,200 cases and
150,085 controls (primarily
of European ancestry)
Two-sample (IVW) No (32)
Gene encoding
molecular target
of
LDL-C-lowering
therapy
(HMGCR)
N = 188,577 (GLSC) 76 Fractures at any skeletal
site confirmed by medical,
radiological, or
questionnaire reports
147,200 cases and
150,085 controls (primarily
of European ancestry)
No
Total serum
calcium
Europeans (discovery
cohort N = 39,400,
replication cohort N =
21,676)
6 Fracture 76,549 cases and 470,164
controls from GEFOS,
EPIC-Norfolk study and UK
Biobank
Two-sample (IVW) No (38)
OR, Odds ratio; IVW, inverse-variance weighted; HR, hazard ratio; THS, thyroid stimulating hormone; LS, lumbar spine; FN, femoral neck.
FIGURE 2 | Vertical and horizontal pleiotropy. (A) Vertical pleiotropy, which does not violate the MR assumption; (B) Horizontal pleiotropy, which violates the
MR assumption.
that only a certain proportion of the genetic instruments have
a horizontal pleiotropic effect. These methods aim to reduce
heterogeneity by removing SNPs that contribute to heterogeneity
disproportionately, based on the standard errors of the Wald
ratios. Such outlier removal strategies are applied in the MR-
PRESSO (50), and generalized summaryMR (GSMR) approaches
(51). One of the issues in applying MR methods that are robust
to pleiotropy is that in order to detect causal effects these require
large sample sizes (49). Another issue concerns the number of
SNPs used as IVs; significant numbers of SNPs are required to
provide sufficient data points for meaningful analysis. However,
an advantage is that these approaches often rely on different
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sets of assumptions, and if consistent, conclusions can be drawn
regarding causality with reasonable confidence.
The recent review by Lawlor et al. provides a useful
summary of the various methods and extensions of Mendelian
Randomization (52). Some of these more advanced MR analysis
methods have been applied in relatively recent studies examining
causal inference in osteoporosis. For example, in their study
examining causal relationships between blood lipids and eBMD,
Cherny et al. found broadly similar inverse associations between
LDL-C and eBMD as assessed by inverse-variance weighted
(IVW), MR-Egger, weighted median and weighted mode
estimates (53). Similarly, in our recent study, MR-Egger, IVW
and weighted median estimates showed similar causal effects of
BMD on sclerostin (54). That said, the statistical evidence against
the null for the MR-Egger estimates was somewhat lower, in both
these papers, reflecting the lower statistical power of this test (48,
49). However, these types of sensitivity analyses have been lacking
in many of the MR analyses in osteoporosis, including those
analyzing a range of metabolites for which genetic influences
could well-exert pleiotropic effects via unknown pathways (38).
It may be hard to exclude pleiotropy where the genetic
instruments comprise just one or two SNPs, however there
are exceptions to this. For example, we recently performed an
MR study to examine the causal relationship between sclerostin
levels and eBMD, based on results of a sclerostin GWAS
where we identified just two loci. However, we were able to
establish a causal relationship between sclerostin and eBMD
using co-localization analysis, which interrogates LD structure at
a single locus, in this case the gene encoding B4GALNT3 (54).
Several analysis methods have been developed to explore
causal pathways in those situations where genetic instruments are
pleiotropically associated with multiple correlated phenotypes.
For example, in studying the causal relationship between
genetically determined BMD (reflected by eBMD) and OA,
Funck-Brentano et al. observed a strong causal effect of BMI on
knee and hip OA, suggesting that if any eBMD SNPs are shared
with BMI, this may influence OA via pathways other than BMD,
which will violate the 3rd MR assumption (horizontal pleiotropy).
The authors established that genetically determined BMD also
has a causal effect on OA after excluding pleiotropic pathways
involving BMI, by removing SNPs from their eBMD polygenic
risk score that were related to BMI (55). Similarly, Cousminer
et al. excluded SNPs for height and BMI in their MR analysis of
the causal role of pubertal age on BMD (33).
An alternative method of accounting for pleiotropy where
genetic variants are pleiotropically associated with multiple
correlated phenotypes, is to perform multivariable MR. The
latter aims to address this limitation by using instruments
associated with multiple exposures to jointly estimate the
separate causal effect of individual risk factors on the outcome
(34, 56–58). For example, Kemp et al. used a one-sample
multivariable method to show that BMI SNPs acted via
both lean and fat mass to increase BMD (34). In an MR
analysis of relationships between plasma lipids and BMD, we
observed a strong inverse association between LDL cholesterol
and forearm BMD in multivariate MR analyses adjusting for
HDL cholesterol and triglycerides, which was not evident
in univariate analyses involving only LDL cholesterol (59).
This indicates that complex relationships may exist between
the causal effects of different lipids and BMD, which MR
analyses need to account for, and may help to explain
the conflicting results from different MR analyses examining
relationships between lipid levels and eBMD in the UK
Biobank (53, 59, 60).
DISTINGUISHING GENETIC CORRELATION
FROM CAUSALITY
Key points:-
1. Traits which are correlated as a result of shared underlying
biology are likely to have shared genetic influences, leading to
a positive signal in MR studies
2. MR signals arising from genetic correlation between two traits
are expected to be bidirectional; true causal effects generally
produce a positive MR signal in one direction only (i.e.,
exposure to outcome as opposed to outcome to exposure)
3. In bidirectional MR, it may be helpful to use methods such as
Steiger filtering to restrict SNPs to those which have strongest
effects on the outcome as opposed to the exposure being tested
4. Though rarer, bidirectional causal effects may exist,
exemplified by a positive causal effect of BMD on sclerostin
levels, and a negative causal effect of sclerostin on BMD.
It’s common for two related traits to share a proportion of
their heritability, as quantified by genetic correlation, implying
some form of shared underlying biology. Bidirectional MR can
help distinguish causality from correlation by first testing the
associations in one direction (i.e., “exposure” to “outcome”),
and then performing these in the opposite direction (i.e.,
“outcome” to “exposure”), using SNPs found to be associated
with each trait in different GWASs. In those instances where
certain SNPs are common to GWASs for both the exposure and
outcome, methods such as Steiger filtering are recommended
to remove these SNPs to ensure they are used correctly as
instruments for analyses in one direction only (61). Bidirectional
MR assumes that the underlying causal association works in
a single direction. Where there is evidence for “bidirectional
causality,” this may simply reflect genetic correlation arising
from a common genetic pathway affecting both the exposure
and outcome. That said, bidirectional Mendelian randomization
can identify causal effects that do work in both directions;
for example, smoking reduces BMI and higher BMI increases
smoking (62). In the case of bidirectional causality where
evidence is stronger in one direction, although the main
causal pathway may be in this direction, findings may
reflect misspecification of the exposure variable as described
above. Alternative strategies to MR, such as latent causal
variable analysis, have been developed to distinguish correlation
from causality (63).
Certain biomarkers and risk factors for osteoporosis may be
unlikely to show strong genetic correlations with BMD, and to
be influenced by common biological pathways, nevertheless it’s
still good practice to perform bidirectional MR. For example,
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in the case of factors such as smoking, which was found to be
genetically related to lower heel BMD (25), in the absence of
bidirectional MR, it’s not possible to exclude reverse causality,
which is not inconceivable given the casual effect of BMI
(which is known to influence BMD) on smoking (62). In
recent studies examining relationships between panels of blood
metabolites and BMD, where the direction of the causal effect is
unclear, whereas one study reported findings from bidirectional
analysis (64), a further one did not (38). In addition, genetic
correlation as a consequence of shared biological pathways
could conceivably explain relationships between BMD and other
disease phenotypes such as osteoarthritis (OA). For example, a
previous study revealed significant genetic correlation between
LS BMD and hip and/or knee OA, suggesting common genetic
influences, exemplified by the SMAD3 locus found to affect
both OA risk and BMD (65). Shared genetic influences on
BMD and OA could also explain recent findings that genetic
instruments for eBMD are associated OA (55); whereas the
authors interpreted this as indicative of a causal effect of eBMD
on OA, bidirectional MR is required to prove such a causal
pathway exists, as opposed to common biological mechanisms
contributing equally to both traits.
One of the challenges in performing bidirectionalMR between
two variables which are highly correlated genetically is that the
two traits are likely to share one or more SNPs in common.
This is particularly an issue when using results derived from
large GWAS studies that generate many signals. For example,
in our recent study of relationships between eBMD and lipids,
a bidirectional effect for eBMD on LDL-C was investigated using
404 eBMD associated SNPs as genetic instruments (12). Steiger
filtering was used to identify SNPs that had stronger effects on
the outcome (LDL-C) compared to the exposure (BMD). This
analysis suggested that 394 of 404 SNPs exerted their primary
effect on BMD as opposed to LDL-C levels. IVW MR, weighted
median MR and MR-Egger regression results showed some
evidence that eBMDmight influence LDL-C, and the association
remained unchanged after Steiger filtering to remove those SNPs
that primary affected LDL-C levels (59).
As well as selectively removing SNPs to assist interpretation
of bidirectional analyses, this approach may also be helpful in
examining the role of specific biological pathways involved in
mediating causal effects. For example, in the above MR analysis
of the effects of plasma lipids on eBMD, we were able to confirm
that the inhibitory effect of LDL cholesterol on eBMD which
we observed was not solely mediated by SNPs intersecting the
HMGR locus which is the target for statin therapy, since similar
results were obtained when SNPs at this locus were removed
from the polygenic risk score. Similarly, SNPs can be stratified
into relevant/specific biological pathways and their association
with outcomes of interest tested. For example, although not a
formal MR analysis, Warrington et al. used genetic risk scores
constructed from SNPs belonging to specific biological pathways,
and showed that genetic risk scores comprising variants that
belonged to the RANK-RANKL-OPG pathway, themesenchymal
stem cell differentiation functional pathway and the WNT
signaling function pathway were associated with bone measures
at age 13, but only mesenchymal stem cell differentiation and the
WNT pathway SNPs showed associations with rate of change in
BMD between 9 and 17 years (66).
It’s a reasonable assumption that correlated variables as a
result of shared biology show equivalent “causal” effects on
bidirectional MR, whereas for a true causal relationship, an effect
is just observed in one direction. However, we recently observed
a further pattern in our study exploring the relationship between
circulating sclerostin levels on eBMD, namely bidirectional
causal pathways in opposite directions (54).We found that higher
levels of serum sclerostin were causally related to lower FN BMD,
lower eBMD and higher fracture risk. In contrast, greater BMD
was causally related to higher sclerostin levels, using BMD SNPs
identified in the GEFOS BMD GWAS (54). This finding aligned
with the observational relationship between BMD and sclerostin
we reported in the same paper and may be a reflection of a
previously unsuspected negative control feedbackmechanism for
BMD (see Figure 3). However, the exact mechanisms involved
remain unclear and functional validation of such a pathway is
still needed.
POWER CONSIDERATIONS
In contrast to conventional epidemiological studies where the
exposure variable comprises the population variance of the
trait of interest, in MR, genetic instruments only capture a
small proportion of trait variance (not infrequently <1%). As
a consequence, the strength of the relationship between an
instrumental variable used for MR, and the outcome of interest,
will only be of a small fraction of that seen for the measured
exposure variable. Therefore, limited power is a common
problem for MR analyses, and a frequent explanation of null
findings, and needs to be an important consideration particularly
when the findings fail to support other well-established lines of
evidence. Limited power is even more problematic for some of
the more recent extensions to MR, such as multivariable MR.
In any given MR study, the major factors governing the power
are the sample size, the strength of the genetic instruments
available, the strength of the underlying causal relationship being
evaluated, and the type I error rate. Recent availability of very
large datasets, such as the UK Biobank, have facilitated well
powered MR studies, as have the increasing number of GWAS
signals available for any given trait. Nonetheless, even where
a large sample is available, MR may be uninformative where
available instruments are lacking, or if there is a weak underlying
relationship. These considerations are particularly important
when null associations are obtained, where it is helpful to report
power calculations to illustrate the strength of any underlying
relationship which would have been detectable, and how this
compares with that seen in observational studies (67).
A related issue is weak instrument bias. In one-sample MR,
using weak instruments may bias the causal association toward
the observational association between the exposure and outcome,
whereas in two-sample MR, weak instruments may bias MR
estimates toward the null (68). Therefore, it is important to
avoid such bias by evaluating instrument strength at the outset
of the study. For most human phenotypes, common genetic
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FIGURE 3 | Proposed feedback pathway between BMD and sclerostin.
Greater BMD is proposed to increase circulating levels of sclerostin, which then
feeds back to inhibit bone formation, and hence limit further gains in BMD.
variants only explain a limited proportion of the variance of
the phenotypes; combining small effects across these common
variants into a score (known as the polygenic risk score) may
increase instrument strength (69). Another relevant concept is
the “NoMeasurement Error” (NOME) assumption of MR, which
assumes the association between a given genetic instrument and
the exposure is estimated without measurement error (70). This
is particularly important when weak instruments are estimated
fromGWASwith small sample sizes. In an IVW setting, themean
F-statistic can be used to assess whether instruments violate the
NOME assumption, a value below 10 implying a high likelihood
of weak instrument bias (71). In an MR-Egger setting, the I2
statistic (between 0 and 1) can be used to quantify violation of the
NOME assumption, a lower value indicating greater likelihood
that this assumption has been violated (48).
In the majority of instances of null findings reported in recent
MR studies of osteoporosis risk factors, genetic instruments have
been identified based on genome-wide significant associations
from large scale GWASs, and although instrument strength is not
universally reported, weak instrument bias is less likely to be an
issue under these circumstances (70). However, weak instrument
bias may be an issue in those instances where instruments have
been identified from relatively small GWAS studies. For example,
in a two-sample MR study examining causal relationships
between inflammation and BMD reporting null findings, three of
the genetic instruments for IL-6 were derived from a population
of 1,664 individuals, and had F-statistics ranging from 3 to 8,
indicating high likelihood of weak instrument bias (29).
FUTURE DIRECTIONS
It may be possible to extend MR to identify novel risk
factors for osteoporosis using a hypothesis-free approach. For
example, centralized databases such as MR-Base (46) and UK
Biobank (http://www.nealelab.is/uk-biobank) have harmonized
GWAS summary results for more than 20,000 complex human
traits. Such resources make it feasible to conduct a phenome-
wide MR for osteoporosis, aimed at identifying novel causal
effects on BMD from screening a comprehensive range of
complex traits. In many cases, mega biobanks such as UK
Biobank, provide the richest source of GWAS-linked exposure
or outcome data. Consequently, the issue of overlapping samples
for generating genetic instruments and providing outcome data
in a two-sample MR framework, potentially providing biased
estimates (8), is becoming increasingly problematic. With the
burgeoning opportunities for performingMR analyses, there also
comes the need to ensure these are performed and reported
comprehensively, with thorough exploration of issues such as
pleiotropy, reverse causality and power, to ensure appropriate
conclusions are drawn. STROBE-MR guidelines, intended to
improve the quality of reporting of MR studies, have recently
been produced (72).
MR was initially developed to examine the causal role of
environmental exposures on the outcome of interest. This
method has since been applied to a wide range of research
areas, including drug target validation and prioritization, and
the interpretation of multi-dimensional omics data. Large-scale
GWASs of omics data, such as metabolites, DNA methylation,
gene expression and protein expression provide a timely
opportunity to identify the causal relationship of thousands of
molecular phenotypes with osteoporosis in a MR framework.
Automated tools such as summary-data-based MR (SMR),
Generalized Summary-data-based MR (GSMR) and the two-
sample MR R package make it possible to conduct such large-
scale analyses effectively (46, 51, 73).
For omics studies of osteoporosis, one of the issues that
needs further consideration is tissue specificity. Most molecular
phenotypes to date have been measured in whole blood, for
which the sample size of expression QTLs and methylation
QTLs studies exceeds 30,000 (74) (http://www.godmc.org.uk/)
and protein QTLs studies exceed 6,000 (75, 76). In contrast, the
QTLs measured in bone tissues are limited to several hundreds of
individuals. Whether molecular phenotypes measured in blood
can be used as a proxy for those measured in bone tissues remains
unclear, particularly methylation which shows a high degree of
tissue specificity, in line with emerging trends in tissue specific
MR (77), implying an urgent need for osteoblasts, osteoclasts and
osteocytes and other skeletal cell types to be sufficiently well-
represented in omics resources.
CONCLUSIONS
MR is being increasingly applied to examine causal inference
in osteoporosis, reflecting the increasing availability of large
datasets such as the UK Biobank, and multiple GWASs for
potential risk factors. To date, the most important findings have
been around the lack of causal role of traditional risk factors
such as vitamin D in determining variation within the normal
range of BMD/fracture risk. High-dimensional omics studies,
based on GWASs of metabolites, gene expression and DNA
methylation, offer exciting opportunities for future discovery,
with the emergence of the first MR studies of metabolites in
osteoporosis. However, an important caveat is that MR studies
can be complicated by a number of issues including horizontal
pleiotropy, reverse causality, and lack of power. Several extended
MR methods have been developed to explore these aspects, and
while not always applied consistently, r STROBE-MR guidelines
have recently been produced, intended to support the quality
with which MR studies are reported.
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